Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
2022 ◽
Vol 7
(1)
◽
pp. 100333
J. Wolf
◽
Å. Helland
◽
I.-J. Oh
◽
M.R. Migliorino
◽
R. Dziadziuszko
◽
...
2019 ◽
Vol 14
(7)
◽
pp. 1233-1243
◽
D. Ross Camidge
◽
Rafal Dziadziuszko
◽
Solange Peters
◽
Tony Mok
◽
Johannes Noe
◽
...
2017 ◽
Vol 12
(1)
◽
pp. S378
◽
D. Ross Camidge
◽
Shirish Gadgeel
◽
Sai-Hong Ou
◽
Leena Gandhi
◽
Gregory Riely
◽
...
Konstantinos Syrigos
◽
Istvan Abert
◽
Zoran Andric
◽
Igor N Bondarenko
◽
Mikhail Dvorkin
◽
...
2017 ◽
Vol 12
(1)
◽
pp. S378-S379
◽
Young Kim
◽
Toyoaki Hida
◽
Hiroshi Nokihara
◽
Masashi Kondo
◽
Koichi Azuma
◽
...
2011 ◽
Vol 71
◽
pp. S44
◽
T. Ciuleanu
◽
L. Stelmakh
◽
S. Cicenas
◽
E. Esteban Gonzalez
2014 ◽
Vol 9
(12)
◽
pp. e114008
◽
Yabing Cao
◽
Guangli Xiao
◽
Xibin Qiu
◽
Sheng Ye
◽
Tongyu Lin
2019 ◽
Vol 25
(10)
◽
pp. 3193-3193
Nicholas Thatcher
◽
Jerome H. Goldschmidt
◽
Michael Thomas
◽
Michael Schenker
◽
Zhiying Pan
◽
...
2012 ◽
Vol 23
◽
pp. ix438-ix439
J. Zugazagoitia
◽
J. Puente
◽
S. Hernandez
◽
J.L. Gonzalez-Larriba
◽
J. Sanz
◽
...
2012 ◽
Vol 23
◽
pp. ix419
◽
S. Wojtowicz-Praga
◽
L. Leon
2012 ◽
Vol 77
(2)
◽
pp. 339-345
◽
Yi-Long Wu
◽
Joo-Hang Kim
◽
Keunchil Park
◽
Adel Zaatar
◽
Gaëlle Klingelschmitt
◽
...
Close
Export Citation Format
Close
Share Document
Close